MARKET

AIMT

Aimmune
AIMT
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-8.6826
3832.22
12.55
2,257,375,397.58
Supreme Court Backs Nestle, Cargill on Child-Slavery Suit
Bloomberg · 16h ago
Nestle Eyes Nature’s Bounty Acquisition to Boost Vitamin Sales
After ditching big chunks of its chocolate and ice cream businesses, Nestle SA Chief Executive Officer Mark Schneider is embracing healthier living by bulking up on vitamins and supplements.
Bloomberg · 04/26 08:22
Contactless Coffee
Nestle wants to get in on the back-to-office push with new contactless Nespresso machines (Source: Quicktake)
Bloomberg · 04/05 21:59
Wall Street Breakfast: Anticipation Builds For iPhone 12
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Anticipation builds for iPhone 12Wedbush is calling today's Apple (AAPL) iPhone event a "once in a decade" potential launch, and the stock is responding accordingly. Shares are up 2% premarket, following a 6.4% advance on Monday, amid expectations that it will be the first iPhone with full 5G capacity and cheaper than last year's devices. Analyst Daniel Ives predicts four iPhone models: 5.4-inch OLED display (starting price: $699); 6.1-inch OLED display ($799), 6.1-inch iPhone Pro OLED
Seekingalpha · 10/13/2020 11:04
Aimmune shareholders accept $2 billion Nestle tender offer
Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic. Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date.
Reuters · 10/13/2020 06:39
Nestle reports 84% holding in Aimmune Therapeutics
Société des Produits Nestlé S.A. ((SPN)), a Nestle (NSRGY) subsidiary announces the results of the tender offer, to purchase all of the outstanding shares of Aimmune Therapeutics' (AIMT) common stock for
Seekingalpha · 10/13/2020 06:16
Are Insiders Buying Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Stock?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Simply Wall St. · 10/06/2020 12:20
Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies
\- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -\- In 2020 to date, Longitude portfolio companies announced 4 IPOs and 3 M&A transactions -MENLO PARK, Calif. and GREENWICH
GlobeNewswire · 09/23/2020 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AIMT. Analyze the recent business situations of Aimmune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AIMT stock price target is 24.75 with a high estimate of 34.50 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 52.86M
% Owned: 80.76%
Shares Outstanding: 65.45M
TypeInstitutionsShares
Increased
70
4.48M
New
48
957.03K
Decreased
34
3.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/Independent Director
Mark McDade
President/Chief Executive Officer/Director
Jayson Dallas
Chief Financial Officer
Eric Bjerkholt
General Counsel/Secretary
Douglas Sheehy
Other
Daniel Adelman
Other
Andrew Oxtoby
Independent Director
Greg Behar
General Manager
Sue Barrowcliffe
Independent Director
Patrick Enright
Independent Director
Kathryn Falberg
Independent Director
Brett Haumann
Independent Director
Mark Iwicki
Independent Director
Stacey Seltzer
No Data

Webull offers kinds of Aimmune stock information, including NASDAQ:AIMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AIMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AIMT stock methods without spending real money on the virtual paper trading platform.